CY1111615T1 - Αρυλβινυλαζακυκλοαλκανια και μεθοδοι παρασκευης και χρησεως τους. - Google Patents
Αρυλβινυλαζακυκλοαλκανια και μεθοδοι παρασκευης και χρησεως τους.Info
- Publication number
- CY1111615T1 CY1111615T1 CY20111100351T CY111100351T CY1111615T1 CY 1111615 T1 CY1111615 T1 CY 1111615T1 CY 20111100351 T CY20111100351 T CY 20111100351T CY 111100351 T CY111100351 T CY 111100351T CY 1111615 T1 CY1111615 T1 CY 1111615T1
- Authority
- CY
- Cyprus
- Prior art keywords
- disorders
- compound
- preparation
- nachr
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Αποκαλύπτεται το βινυλαζακυκλοαλκάνιο 3-(2-πυρρολιδιν-3-υλβινυλ)-5-(τετραϋδροπυραν-4-υλοξυ)πυριδίνη. Η ένωση είναι ένα πρόσδεμα των nAChR. Η ένωση και τα φαρμακευτικά αποδεκτά άλατα της μπορεί να χρησιμοποιηθεί για την παρασκευή φαρμακευτικών συνθέσεων και/ή φαρμάκων προοριζόμενων για την πρόληψη ή την αγωγή διαταραχών σχετιζόμενων με δυσλειτουργία του nAChR, ιδιαίτερα εντός του κεντρικού νευρικού συστήματος ή του γαστρεντερικού συστήματος. Παραδείγματα τύπων διαταραχών οι οποίες μπορούν να αντιμετωπισθούν περιλαμβάνουν νευροεκφυλιστικές διαταραχές, περιλαμβανομένων διαταραχών του κεντρικού νευρικού συστήματος όπως η νόσος του Alzheimer, νοητικές διαταραχές, κινητικές διαταραχές όπως η νόσος του Parkinson, τον εθισμό σε φάρμακα, διαταραχές της συμπεριφοράς και φλεγμονώδεις διαταραχές εντός του γαστρεντερικού συστήματος. Η ένωση μπορεί επίσης να χρησιμεύσει ως αναλγητικά στην αγωγή του οξέως, χρόνιου ή υποτροπιάζοντος άλγους.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/379,868 US7098331B2 (en) | 2003-03-05 | 2003-03-05 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
| EP09075124A EP2085395B1 (en) | 2003-03-05 | 2004-03-04 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1111615T1 true CY1111615T1 (el) | 2015-10-07 |
Family
ID=32926772
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081100831T CY1110391T1 (el) | 2003-03-05 | 2008-08-06 | Αρυλβινυλαζακυκλοαλκανια και μεθοδοι παρασκευης και χρησεως τους |
| CY20111100351T CY1111615T1 (el) | 2003-03-05 | 2011-04-05 | Αρυλβινυλαζακυκλοαλκανια και μεθοδοι παρασκευης και χρησεως τους. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081100831T CY1110391T1 (el) | 2003-03-05 | 2008-08-06 | Αρυλβινυλαζακυκλοαλκανια και μεθοδοι παρασκευης και χρησεως τους |
Country Status (31)
| Country | Link |
|---|---|
| US (8) | US7098331B2 (el) |
| EP (3) | EP1601670B1 (el) |
| JP (3) | JP4663627B2 (el) |
| KR (4) | KR100953150B1 (el) |
| CN (3) | CN100526308C (el) |
| AR (3) | AR043469A1 (el) |
| AT (3) | ATE496046T1 (el) |
| AU (3) | AU2004217903B2 (el) |
| BR (1) | BRPI0409576A (el) |
| CA (1) | CA2516514C (el) |
| CL (1) | CL2004000452A1 (el) |
| CY (2) | CY1110391T1 (el) |
| DE (2) | DE602004031165D1 (el) |
| DK (2) | DK2085395T3 (el) |
| EA (3) | EA010870B1 (el) |
| ES (3) | ES2385941T3 (el) |
| GT (1) | GT200400033A (el) |
| IL (3) | IL170155A (el) |
| JO (1) | JO2488B1 (el) |
| MX (1) | MXPA05009386A (el) |
| NO (3) | NO331920B1 (el) |
| NZ (1) | NZ541795A (el) |
| PA (1) | PA8597201A1 (el) |
| PE (1) | PE20040930A1 (el) |
| PL (5) | PL216979B1 (el) |
| PT (2) | PT2085395E (el) |
| SI (2) | SI1601670T1 (el) |
| TW (3) | TWI339662B (el) |
| UY (1) | UY28218A1 (el) |
| WO (1) | WO2004078752A1 (el) |
| ZA (1) | ZA200506790B (el) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7098331B2 (en) * | 2003-03-05 | 2006-08-29 | Targacept, Inc. | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
| FR2896800B1 (fr) * | 2006-01-30 | 2008-04-11 | Servier Lab | Nouveaux composes pyridinylaminoalkylene-et pyridinyloxyalkylene-cyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| WO2008157365A2 (en) * | 2007-06-15 | 2008-12-24 | Targacept, Inc. | Vinylazacycloalkanes for treating neuropathic pain |
| EP2296640A1 (en) * | 2008-05-12 | 2011-03-23 | Targacept Inc. | Methods for preventing the development of retinopathy by the oral administration of nnr ligands |
| TW201024283A (en) | 2008-12-01 | 2010-07-01 | Targacept Inc | Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine |
| US9145396B2 (en) | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
| KR20110098763A (ko) * | 2008-12-01 | 2011-09-01 | 타가셉트 인코포레이티드 | (ｒ)-5-((ｅ)-2-(피롤리딘-3-일비닐)피리미딘의 합성 및 그의 신규한 염 형태 |
| WO2010080757A2 (en) | 2009-01-07 | 2010-07-15 | Astrazeneca Ab | Combinations with an alpha-4beta-2 nicotinic agonist |
| US20120157477A1 (en) * | 2009-06-17 | 2012-06-21 | Targacept, Inc. | Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands |
| AU2010328419A1 (en) | 2009-12-07 | 2012-06-21 | Targacept, Inc. | 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands |
| US20130237550A1 (en) * | 2010-03-11 | 2013-09-12 | Targacept, Inc. | Arylvinylazacycloalkane compounds for constipation |
| US20110274628A1 (en) * | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
| US20140081714A1 (en) * | 2012-09-19 | 2014-03-20 | Salesforce.Com, Inc. | Systems and methods of rewarding users in an on-demand system |
| US20140278929A1 (en) * | 2013-03-15 | 2014-09-18 | Yahoo! Inc. | System and method identifying opportunities for advertising entities based on user goal achievement |
| PT3439661T (pt) * | 2016-04-07 | 2021-09-30 | Oyster Point Pharma Inc | Métodos de tratamento de condições oculares |
| KR101848601B1 (ko) * | 2016-07-27 | 2018-04-12 | 송기봉 | 일회용 위생 티슈 |
| EP3820443A1 (en) | 2018-07-10 | 2021-05-19 | Oyster Point Pharma, Inc. | Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions |
| TW202019424A (zh) | 2018-07-10 | 2020-06-01 | 美商奧伊斯特普安生物製藥公司 | 治療眼部症狀之方法 |
| EP4142734B1 (en) | 2020-04-28 | 2025-08-20 | Oyster Point Pharma, Inc. | Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989000158A1 (en) | 1987-07-02 | 1989-01-12 | Pfizer Inc. | Bridged-diazabicycloalkyl quinolone carboxylic acids and esters |
| US4922901A (en) * | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
| US5187166A (en) * | 1990-07-31 | 1993-02-16 | Nisshin Flour Milling Co., Ltd. | Azabicyclo derivatives and their use as antiemetics |
| IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
| US5852041A (en) * | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
| IT1274018B (it) * | 1994-02-23 | 1997-07-14 | Riace Ets | Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica |
| GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
| US5604231A (en) * | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
| US5597919A (en) * | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5583140A (en) * | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
| US5616716A (en) * | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
| AT403803B (de) | 1996-04-19 | 1998-05-25 | Sanochemia Ltd | Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln |
| US5663356A (en) * | 1996-04-23 | 1997-09-02 | Ruecroft; Graham | Method for preparation of aryl substituted alefinic secondary amino compounds |
| US5629325A (en) | 1996-06-06 | 1997-05-13 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
| US6437138B1 (en) * | 1996-06-06 | 2002-08-20 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
| ATE278670T1 (de) | 1997-10-27 | 2004-10-15 | Neurosearch As | Heteroaryl diazacycloalkane als cholinergische ligande für nikotin-acetylcholin-rezeptoren |
| JP2003501416A (ja) | 1999-06-07 | 2003-01-14 | ターガセプト，インコーポレイテッド | 医薬組成物およびその使用法 |
| EP1212319A2 (en) | 1999-09-14 | 2002-06-12 | Abbott Laboratories | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
| JP2003513054A (ja) | 1999-11-01 | 2003-04-08 | ターガセプト，インコーポレイテッド | アリールオレフィンアザ環式化合物及びアリールアセチレンアザ環式化合物、それらを含有する薬剤組成物、及び、ニコチンコリン作動性受容体の阻害薬としてのそれらの使用 |
| US6624167B1 (en) * | 2000-08-04 | 2003-09-23 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| AU2002322562A1 (en) | 2001-07-19 | 2003-03-03 | Medical College Of Georgia Research Institute | Novel analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders |
| US7098331B2 (en) * | 2003-03-05 | 2006-08-29 | Targacept, Inc. | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
-
2003
- 2003-03-05 US US10/379,868 patent/US7098331B2/en not_active Expired - Lifetime
-
2004
- 2004-02-10 TW TW093103017A patent/TWI339662B/zh not_active IP Right Cessation
- 2004-02-10 TW TW098105932A patent/TW200927746A/zh unknown
- 2004-02-10 TW TW098105931A patent/TWI377204B/zh not_active IP Right Cessation
- 2004-03-02 PE PE2004000228A patent/PE20040930A1/es not_active Application Discontinuation
- 2004-03-04 ES ES09075124T patent/ES2385941T3/es not_active Expired - Lifetime
- 2004-03-04 WO PCT/US2004/006530 patent/WO2004078752A1/en not_active Ceased
- 2004-03-04 UY UY28218A patent/UY28218A1/es not_active Application Discontinuation
- 2004-03-04 EP EP04717398A patent/EP1601670B1/en not_active Expired - Lifetime
- 2004-03-04 JO JO200422A patent/JO2488B1/en active
- 2004-03-04 SI SI200430775T patent/SI1601670T1/sl unknown
- 2004-03-04 JP JP2006509059A patent/JP4663627B2/ja not_active Expired - Fee Related
- 2004-03-04 ES ES08075106T patent/ES2389106T3/es not_active Expired - Lifetime
- 2004-03-04 DE DE602004031165T patent/DE602004031165D1/de not_active Expired - Lifetime
- 2004-03-04 SI SI200431638T patent/SI2085395T1/sl unknown
- 2004-03-04 CN CNB2004800060242A patent/CN100526308C/zh not_active Expired - Lifetime
- 2004-03-04 GT GT200400033A patent/GT200400033A/es unknown
- 2004-03-04 DK DK09075124.9T patent/DK2085395T3/da active
- 2004-03-04 CN CNA2008100917335A patent/CN101255155A/zh active Pending
- 2004-03-04 NZ NZ541795A patent/NZ541795A/en not_active IP Right Cessation
- 2004-03-04 AR ARP040100690A patent/AR043469A1/es not_active Application Discontinuation
- 2004-03-04 PT PT09075124T patent/PT2085395E/pt unknown
- 2004-03-04 CA CA2516514A patent/CA2516514C/en not_active Expired - Lifetime
- 2004-03-04 KR KR1020097002099A patent/KR100953150B1/ko not_active Expired - Fee Related
- 2004-03-04 AT AT09075124T patent/ATE496046T1/de active
- 2004-03-04 CN CN2009100048828A patent/CN101550132B/zh not_active Expired - Fee Related
- 2004-03-04 DK DK04717398T patent/DK1601670T3/da active
- 2004-03-04 EP EP09075124A patent/EP2085395B1/en not_active Expired - Lifetime
- 2004-03-04 DE DE602004013553T patent/DE602004013553D1/de not_active Expired - Lifetime
- 2004-03-04 AT AT04717398T patent/ATE394394T1/de active
- 2004-03-04 EA EA200501425A patent/EA010870B1/ru active IP Right Revival
- 2004-03-04 BR BRPI0409576-6A patent/BRPI0409576A/pt not_active IP Right Cessation
- 2004-03-04 PL PL378415A patent/PL216979B1/pl unknown
- 2004-03-04 PT PT04717398T patent/PT1601670E/pt unknown
- 2004-03-04 EP EP08075106A patent/EP1947100B1/en not_active Expired - Lifetime
- 2004-03-04 PA PA20048597201A patent/PA8597201A1/es unknown
- 2004-03-04 EA EA200801764A patent/EA014714B1/ru not_active IP Right Cessation
- 2004-03-04 AT AT08075106T patent/ATE517893T1/de not_active IP Right Cessation
- 2004-03-04 KR KR1020127001576A patent/KR20120014236A/ko not_active Ceased
- 2004-03-04 PL PL394604A patent/PL215059B1/pl unknown
- 2004-03-04 MX MXPA05009386A patent/MXPA05009386A/es active IP Right Grant
- 2004-03-04 PL PL04717398T patent/PL1601670T3/pl unknown
- 2004-03-04 PL PL09075124T patent/PL2085395T3/pl unknown
- 2004-03-04 KR KR1020097002098A patent/KR101018083B1/ko not_active Expired - Fee Related
- 2004-03-04 EA EA200900706A patent/EA019240B1/ru not_active IP Right Cessation
- 2004-03-04 PL PL394600A patent/PL394600A1/pl unknown
- 2004-03-04 ES ES04717398T patent/ES2309507T3/es not_active Expired - Lifetime
- 2004-03-04 AU AU2004217903A patent/AU2004217903B2/en not_active Ceased
- 2004-03-04 KR KR1020057016343A patent/KR101185541B1/ko not_active Expired - Fee Related
- 2004-03-08 CL CL200400452A patent/CL2004000452A1/es unknown
-
2005
- 2005-08-08 IL IL170155A patent/IL170155A/en active IP Right Grant
- 2005-08-17 US US11/206,243 patent/US20060094732A1/en not_active Abandoned
- 2005-08-24 ZA ZA200506790A patent/ZA200506790B/xx unknown
- 2005-09-05 NO NO20054120A patent/NO331920B1/no not_active IP Right Cessation
-
2008
- 2008-08-06 CY CY20081100831T patent/CY1110391T1/el unknown
- 2008-08-07 US US12/187,584 patent/US7714001B2/en not_active Expired - Lifetime
- 2008-12-17 AU AU2008258188A patent/AU2008258188B2/en not_active Ceased
- 2008-12-17 AU AU2008258187A patent/AU2008258187B2/en not_active Ceased
-
2009
- 2009-01-05 US US12/348,605 patent/US8063068B2/en not_active Expired - Lifetime
- 2009-02-05 AR ARP090100388A patent/AR070569A2/es not_active Application Discontinuation
- 2009-02-05 AR ARP090100389A patent/AR070570A2/es not_active Application Discontinuation
- 2009-04-05 IL IL197890A patent/IL197890A/en active IP Right Grant
- 2009-04-05 IL IL197889A patent/IL197889A/en active IP Right Grant
- 2009-05-14 NO NO20091888A patent/NO332293B1/no not_active IP Right Cessation
- 2009-06-09 NO NO20092231A patent/NO20092231L/no unknown
- 2009-07-31 JP JP2009178897A patent/JP5537085B2/ja not_active Expired - Lifetime
- 2009-07-31 JP JP2009178896A patent/JP5537084B2/ja not_active Expired - Lifetime
-
2010
- 2010-01-06 US US12/683,106 patent/US8067443B2/en not_active Expired - Fee Related
-
2011
- 2011-02-24 US US13/033,719 patent/US8633222B2/en not_active Expired - Lifetime
- 2011-04-05 CY CY20111100351T patent/CY1111615T1/el unknown
-
2013
- 2013-12-17 US US14/108,918 patent/US20140107164A1/en not_active Abandoned
-
2015
- 2015-02-24 US US14/629,517 patent/US20150164894A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111615T1 (el) | Αρυλβινυλαζακυκλοαλκανια και μεθοδοι παρασκευης και χρησεως τους. | |
| CY1110405T1 (el) | Φαρμακευτικες συνθεσεις περιλαμβανοντας δεξτρομεθορφανη και κινιδινη για την αγωγη νευρολογικων διαταραχων | |
| ATE253918T1 (de) | Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel | |
| CY1106645T1 (el) | Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος | |
| NL970006I2 (nl) | Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson. | |
| DK1104758T3 (da) | Acetylenderivativer som anti-inflammatoriske/analgesiske lægemidler | |
| DE60219954D1 (de) | Neue Indol-2-on Derivate | |
| CY1108514T1 (el) | Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων | |
| DE602004024565D1 (de) | Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems | |
| ATE209908T1 (de) | RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN | |
| DK1632483T3 (da) | Heterocykliske, substituerede carbonylderivater og deres anvendelse som dopamin-D3-receptorligander | |
| PT757685E (pt) | Novas amidas ciclicas como incrementadores de libertacao de neurotransmissores | |
| DE602004016376D1 (de) | Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs | |
| DE69824313D1 (de) | Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen | |
| NO20031410L (no) | Anvendelse av distamycinderivater for fremstilling av medikamenter | |
| FI954614A0 (fi) | Imidatsolokinoksalinonijohdannaiset EAA-antagonisteina | |
| DE60108130D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
| ATE228843T1 (de) | Verwendung von desoxypeganin zur behandlung von drogenabhängigkeit | |
| TW200510331A (en) | Heteroaryl-substituted imidazole derivatives | |
| ATE445401T1 (de) | Verwendung von opioid-rezeptorantagonisten zur prävention und/oder behandlung von erkrankungen im zusammenhang mit dem target calcineurin | |
| WO2005094497A3 (en) | Systemic delivery of therapeutics to central nervous system | |
| SE9302334D0 (sv) | New compounds | |
| RU2003124971A (ru) | Способ лечения больных с невротическими и соматоформными расстройствами | |
| JP2006514659A5 (el) | ||
| RU99107828A (ru) | Способ лечения патологического влечения к наркотикам у больных опийной наркоманией |